Global Oncology & Cancer Drugs Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Oncology & Cancer Drugs Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Oncology & Cancer is a group of diseases caused by the uncontrolled growth and division of abnormal cells. Oncology & Cancer Drugs refers to drugs that treat tumors and cancer. These drugs treat tumors and cancers by killing or inhibiting cancer cells in a variety of ways. Common Oncology & Cancer Drugs can be divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), hormonal therapy and others.

Market Overview:

The latest research study on the global Oncology & Cancer Drugs market finds that the global Oncology & Cancer Drugs market reached a value of USD 222096.07 million in 2022. It’s expected that the market will achieve USD 433292.18 million by 2028, exhibiting a CAGR of 11.78% during the forecast period.

Market size of Oncology & Cancer Drugs products expands during forecast period

According to the World Health Organization, cancer is the leading cause of death globally, killing nearly 10 million people, or nearly one in six deaths, in 2020. Of these, the most common cancers are breast, lung, colon and rectal cancers, and prostate cancer. At the same time, with the increase of age, the cell's self-repair function gradually decreases. Under the stimulation of the accumulation of various carcinogenic factors, the cell function is disordered, and under the action of various factors such as hypertension, diabetes, chronic obstructive pulmonary disease, and other malignant tumors of other organs, the incidence of cancer in the elderly population has risen sharply. In the future, the aging of the global population will continue to increase the number of cancer patients, thereby increasing the market demand for oncology & cancer drugs.

Strict supervision of Oncology & Cancer Drugs in various countries

Oncology & Cancer Drugs are products directly related to the health of citizens. Therefore, relevant drug regulatory agencies around the world have formulated a series of laws and regulations on the access, product licensing, marketing, and use of the Oncology & Cancer Drugs industry to strengthen the supervision of the Oncology & Cancer Drugs industry. The research and development, production, sales and import of Oncology & Cancer Drugs are strictly regulated by relevant national laws and regulations. It is difficult for companies lacking relevant business qualifications to enter the bladder cancer drug industry. Common anticancer drug regulatory agencies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Chinese National Medical Products Administration (NMPA), and more.

Region Overview:

In global comparison, a significant portion of the revenue was generated in North America (46.13% in 2021).

Company Overview

Bristol-Myers Squibb is one of the major players operating in the Oncology & Cancer Drugs market, holding a share of 15.16% in 2022.

Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Bristol-Myers Squibb's medicines help millions of patients worldwide in disease areas such as oncology, cardiovascular, immunoscience, fibrosis and more. Bristol-Myers Squibb has built a sustainable pipeline of potential therapies and is using translational medicine and data analytics to understand how Bristol-Myers Squibb can deliver the right medicine to the right patient at the right time for optimal outcomes.

Roche

Roche is a global pioneer in pharmaceuticals and diagnostics, focused on advancing science to improve people's lives. The combined strengths of medicines and diagnostics have made Roche a leader in personalised healthcare-a strategy aimed at delivering the right treatment to every patient in the best possible way.

Segmentation Overview:

Among different product types, Targeted Therapy segment is anticipated to contribute the largest market share in 2027.

Chemotherapy

Chemotherapy drugs are chemical agents that work by destroying fast-growing cells in the body. Cancer cells grow and divide more rapidly than other cells. The goal of chemotherapy is to lower the total number of cancer cells in your body and reduce the chances that the cancer will spread to other parts of the body (metastasize).

Targeted Therapy

Targeted therapies are part of a new approach known as personalized medicine or precision medicine. Targeted therapies are able to seek out and kill cancerous cells without harming the normal cells in your body. These drugs work by blocking the molecular pathways that are critical to tumor growth.

Immunotherapy (Biologic Therapy)

Immunotherapy is a type of targeted therapy that uses the body's own immune system to attack cancer cells. Cancer cells sometimes have strategic ways of hiding from patient's immune system, but immunotherapies work by blocking these mechanisms.

Hormonal Therapy

Hormone therapy is used to treat cancers that rely on hormones to grow. This may include certain types of breast cancer and prostate cancer. Breast cancers may be fed by estrogen or progesterone, while prostate cancers often depend on the hormone androgen.

Application Overview:

The market's largest segment by application is the segment Solid Tumors, with a market share of 78.05% in 2021.

Blood Cancers

Blood Cancers are cancers that start in the bone marrow, which produces blood. Blood cancers include non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), multiple myeloma (MM) and others.

Solid Tumors

Solid tumors can develop in the muscles, bones, and organs of the body. Solid tumors include non-small cell lung cancer (NSCLC), pure red cell aplasia (PRCA), BRCA gene mutations, triple negative breast cancer (TNBC), ovarian cancer, colorectal cancer and others.

Key Companies in the global Oncology & Cancer Drugs market covered in Chapter 3:

Teva
Astellas
Otsuka
Sanofi
Pfizer
AstraZeneca
Bayer
Merck KGaA
Novartis
Eli Lilly
Roche
Eisai
Amgen
Takeda
Gilead Sciences
Johnson & Johnson
Ipsen
Bristol-Myers Squibb
AbbVie
Merck & Co.

In Chapter 4 and Chapter 14.2, on the basis of types, the Oncology & Cancer Drugs market from 2018 to 2029 is primarily split into:

Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Oncology & Cancer Drugs market from 2018 to 2029 covers:

Blood Cancers
Solid Tumors

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)